Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Cardinal Health to $94 from $96 and keeps an Underweight rating on the shares following the recently announced loss of the Optum contract and also for Cardinal’s re-segmentation. The firm’s 2025/2026 EPS estimates decrease by about 2%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cardinal Health price target lowered to $110 from $118 at Evercore ISI
- Cardinal Health Announces New Business Structure and Segments
- Cardinal Health weakness a buying opportunity, says Baird
- McKesson won OptumRx contract lost by Cardinal, says Evercore
- Cardinal Health Ends Pharmaceutical Distribution Deal with OptumRx